Product Description
Mechanisms of Action: S1R Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Chile | Egypt | France | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Lebanon | Luxembourg | Malaysia | Netherlands | Norway | Pakistan | Peru | Russia | Saudi Arabia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: INFECTOPHARM Arzneimittel und Consilium
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Healthy Volunteers
Phase 2: Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2019-002012-12 | P4 |
Active, not recruiting |
Healthy Volunteers |
2021-12-06 |
|
2014-003151-62 | P4 |
Terminated |
Healthy Volunteers |
2015-01-30 |
|
COU-NOS-001 | P1 |
Terminated |
Multiple Myeloma |
2010-07-01 |
|
0C-99-16 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin |
2006-12-01 |